SOMAí Pharmaceuticals July 2023 Newsletter

Newsletter

July 2023

As we approach our product launch in September, SOMAí had a highly active July.

We are excited to share that our?APIs have successfully reached one-year stability?(six months accelerated stability), and the testing is ongoing. As a result, we will offer a diverse range of APIs catering to numerous markets. We have multiple single-strain cultivars in both?crude THC extract?and?Purified THC distillate?to offer. Products will be available for sale in September.

Learn more about our products here.

We have expanded our global presence with the inauguration of an?office?in?Australia. Furthermore, we are still working on our distribution license in?Germany?and will offer representatives in?Poland,?Italy, and?the?UK?to start. These representatives will be the face of our company, ensuring efficient communication and assistance for distributors, doctors, and patients. SOMAí looks forward to fostering new partnerships in other regions as we progress with our go-to-market.

We are almost done with?phase two of our expansion, targeting room certification in August. This expansion elevates our capabilities, broadens product range, and adds clean room production space. It includes a dedicated area for soft gel capsule production, sublingual and transdermal tab production, a specialized room for vape cartridge and syringe filling, and two new packaging lines.

SOMAí has submitted a?pre-grant application?to accelerate our?R&D?effort. It includes developing new formulations and generic medicine. Specifically, it aims to develop:

• New improved formulation based on sublingual drops to increase the bioavailability of oral cannabinoids;
• Formulation of a generic THC:CBD 1:1 drug with a Phase 1 bioequivalence clinical trial.

With ambitious goals, SOMAí aims to become a leader in the cannabinoid pharmaceutical industry, providing a better quality of life.

SOMAí Pharmaceuticals has renewed the?partnership with Lusófona University/CBIOS?for formulation development this month. According to this partnership, Lusófona will develop lab-scale formulations and perform corresponding stability testing. The collaboration will also encompass "In Vitro," "In Vivo" (animal model), and finely-tuned "In Human" absorption studies. To ensure the successful execution of these studies, a team of skilled human resources will be provided to offer comprehensive support and oversight. This collaboration aims to leverage the expertise of both SOMAí Pharmaceuticals and Lusófona University in the pursuit of advancements in formulation development.

SOMAí?- August highlights:?

Michael Sassano is embarking on a business tour across Australia and will attend?Australian Medicinal Cannabis Symposium in Brisbane. Furthermore, he will visit Cape Town and Johannesburg in?South Africa, and?Lesotho. If you are interested in scheduling a meeting to explore potential collaborations with SOMAí Pharmaceuticals, please feel free to reach out to?[email protected].

Check our latest useful links

• You can get information about SOMAí products and services in the Product Catalogue.
• SOMAí Pharmaceuticals?SOMAí Equity Research.

Latest articles from our CEO, Michael Sassano

• Unpacking the New German Cannabis Reform Bill
• Albania Officially Green Lights Medical and Industrial Cannabis Cultivation
• What Is The Cannabis Edge In Germany, Australia, And The UK
• A global market access journey in cannabinoid pharmaceuticals
• European Cannabis Social Clubs Explained
• Opinion: Where Germany’s Recreational Cannabis Plan Could Go Next

More videos & articles?here.